share_log
Breakings ·  Aug 28 04:20
Arcus Biosciences: Facility Adds Operational Flexibility & Provides Funding for Recently Announced Phase 3 Peak-1 Study for Casdatifan.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment